iPSC derived Cardiomyocytes for Predicting and Removing Drug Cardiotoxicity - Mark Mercola

iPSC derived Cardiomyocytes for Predicting and Removing Drug Cardiotoxicity - Mark Mercola

Cardiac Stem Cells - Anthony DeMaria, Deepak Srivistava, Mark Mercola, Deborah LieuПодробнее

Cardiac Stem Cells - Anthony DeMaria, Deepak Srivistava, Mark Mercola, Deborah Lieu

Accurate Prediction of On- and Off-target Cardiotoxicity with Human iPSC-Derived CardiomyocytesПодробнее

Accurate Prediction of On- and Off-target Cardiotoxicity with Human iPSC-Derived Cardiomyocytes

Accurate Prediction of On- and Off-Target Cardiotoxicity with Human iPSC-Derived CardiomyocytesПодробнее

Accurate Prediction of On- and Off-Target Cardiotoxicity with Human iPSC-Derived Cardiomyocytes

Re-introducing the Patient Context into Cardiac Drug Discovery Using iPSCsПодробнее

Re-introducing the Patient Context into Cardiac Drug Discovery Using iPSCs

Investigative in vitro Drug Toxicology with Human iPSC derived CardiomyocytesПодробнее

Investigative in vitro Drug Toxicology with Human iPSC derived Cardiomyocytes

Cardiotoxicity assay in iPSC derived cardiomyocytesПодробнее

Cardiotoxicity assay in iPSC derived cardiomyocytes

M. Mercola - Development of a Pharmacological Approach to Myocardial RegenerationПодробнее

M. Mercola - Development of a Pharmacological Approach to Myocardial Regeneration

Accurate Clinical Concentration-Response Predictions for Cardiac Arrhythmias..Подробнее

Accurate Clinical Concentration-Response Predictions for Cardiac Arrhythmias..

Using Human Stem Cell-derived Cardiomyocytes to Investigate In Vitro Human Cardiomyocyte BiologyПодробнее

Using Human Stem Cell-derived Cardiomyocytes to Investigate In Vitro Human Cardiomyocyte Biology

Human iPSC-Derived Cardiomyocyte Networks For Recurrent AP RecordingsПодробнее

Human iPSC-Derived Cardiomyocyte Networks For Recurrent AP Recordings

High-Throughput Assessment of Compound-Induced Cardiotoxicity Using Human iPSC-Derived CardiomyocyteПодробнее

High-Throughput Assessment of Compound-Induced Cardiotoxicity Using Human iPSC-Derived Cardiomyocyte

Cardiac iPSCs for Disease Modeling and Drug DiscoveryПодробнее

Cardiac iPSCs for Disease Modeling and Drug Discovery

Hepatotoxicity using iPSC-derived liver cells and beating pattern in iPSC-derived cardiac spheroidsПодробнее

Hepatotoxicity using iPSC-derived liver cells and beating pattern in iPSC-derived cardiac spheroids

Predictive Human Induced Pluripotent Stem Cell-derived Cardiomyocyte Model of CardiotoxicityПодробнее

Predictive Human Induced Pluripotent Stem Cell-derived Cardiomyocyte Model of Cardiotoxicity

Utilizing Stem Cell-derived Cardiomyocytes for Early Safety Screening - Webinar PresentationПодробнее

Utilizing Stem Cell-derived Cardiomyocytes for Early Safety Screening - Webinar Presentation

Mark Mercola, Ph.D. - November 27, 2012Подробнее

Mark Mercola, Ph.D. - November 27, 2012

Cardiac proarrhythmic risk assessment using human iPSC-derived cardiomyocytes - Session 2Подробнее

Cardiac proarrhythmic risk assessment using human iPSC-derived cardiomyocytes - Session 2

Using Patient Specific iPSC-Cardiomyocytes for Disease ModelingПодробнее

Using Patient Specific iPSC-Cardiomyocytes for Disease Modeling

Stem Cell derived cells for Drug discovery | Protocol PreviewПодробнее

Stem Cell derived cells for Drug discovery | Protocol Preview

Актуальное